Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement
Highlights • HFrEF is a debilitating disease with substantial morbidity, mortality, and costs. • SGLT2i reduce adverse cardiovascular (including HF) and renal events. • SGLT2i have ushered in a new…